Physician profile
Juan Bautista Iribarren
NPI 1720283336
$915,403.36
in general payments reported to CMS, 2019-2025
37 companies · $224K in 2025
The $224K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $112K · 2021: $71K · 2022: $82K · 2023: $78K · 2024: $260K · 2025: $224K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $493K · Travel and Lodging: $43K · Food and Beverage: $14K · Consulting Fee: $11K · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $492,667.61 |
| Travel and Lodging | $43,315.18 |
| Food and Beverage | $13,721.11 |
| Consulting Fee | $11,156.00 |
| Education | $113.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $368,939.97 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Genzyme Corporation | $332,354.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $167,903.36 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Regeneron Healthcare Solutions, INC. | $38,983.92 | 2021-2025 | Dupixent |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $996.26 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Boston Scientific Corporation | $826.99 | 2020-2023 | Acquire |
| Insmed, INC. | $787.74 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $756.68 | 2019-2025 | Ofev, Jascayd |
| Pfizer INC. | $311.06 | 2019-2024 | |
| Philips North America LLC | $304.35 | 2019-2025 | Vest Therapy Und |
| Mylan Specialty L.P. | $221.98 | 2019-2021 | |
| Inspire Medical Systems, INC. | $150.67 | 2023-2025 | Inspire |
| Amgen INC. | $120.85 | 2021-2025 | Tezspire |
| Gilead Sciences, INC. | $118.21 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $109.17 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $100.93 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $87.94 | 2020-2021 | |
| Electromed, INC. | $81.64 | 2023 | Smartvest |
| Ethicon US, LLC | $78.57 | 2019 | |
| Baxter Healthcare | $64.35 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Viatris Specialty LLC | $63.56 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $57.99 | 2022 | |
| Circassia INC. | $50.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $46.74 | 2023-2024 | |
| Verona Pharma, INC. | $42.82 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $42.74 | 2020-2021 | |
| Abbvie INC. | $42.10 | 2023-2024 | |
| Inogen, INC. | $36.41 | 2020-2024 | |
| Melinta Therapeutics, LLC | $20.32 | 2021 | |
| Vapotherm INC | $18.46 | 2024 | Vapotherm |
| Bayer Healthcare Pharmaceuticals INC. | $17.17 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.16 | 2019 | |
| Nuwellis, INC. | $16.72 | 2024 | Aquadex Smartflow Console |
| Pulmonx Corporation | $16.05 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Ars Pharmaceuticals Operations, INC. | $14.76 | 2025 | Neffy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Iribarren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.